A drug target is a molecule inside or on the surface of a cell that a drug binds to in order to change how that cell behaves. In most cases, the target is a protein, though researchers are increasingly designing therapies that act on other molecules like RNA. The concept matters because choosing the right target is the single most consequential decision in drug development: get it right and you have a medicine that treats disease with manageable side effects; get it wrong and years of work and billions of dollars lead nowhere. Roughly 35% of all approved drugs act on just one family of protein targets, which gives a sense of how concentrated and high-stakes the field is.
What Counts as a Drug Target
When scientists say “drug target,” they mean the specific biological molecule a drug is designed to interact with. Usually this is a protein that plays a role in a disease process. The drug binds to the target and either blocks its normal function, enhances it, or changes its behavior in some therapeutically useful way. Think of it like a lock and key: the target is the lock, and the drug is a key shaped to fit it in a particular way.
Not every protein in the body qualifies. To be a useful drug target, a molecule generally needs to meet a few criteria. It should be involved in the disease you want to treat. Altering its activity should produce a beneficial outcome without causing too much collateral damage elsewhere. And there should be a physical site on the protein where a drug molecule can actually latch on. That last requirement, whether a target has a suitable binding pocket, is what researchers call “druggability.” Automated computational methods now scan a protein’s three-dimensional structure looking for pockets of the right size, shape, and chemical character to accommodate a drug-like molecule.1PubMed. Structure-based druggability assessment–identifying suitable targets for small molecule therapeutics
The Major Protein Families That Drugs Act On
The human body makes thousands of different proteins, but the vast majority of approved drugs cluster around a handful of protein families. The biggest single group is G protein-coupled receptors, or GPCRs. These are proteins embedded in cell membranes that detect signals from outside the cell, including hormones, neurotransmitters, and sensory stimuli like light and odor. GPCRs are involved in nearly every major physiological process, and about 36% of all approved drugs act on them.2PubMed Central. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? That includes drugs for heart disease, diabetes, obesity, depression, pain, and asthma, among many others. The superfamily includes around 800 members in humans, and roughly 100 of the non-sensory ones are still “orphan” receptors whose natural signaling molecules remain unknown, meaning there could be untapped therapeutic opportunities waiting to be found.3Experimental & Molecular Medicine. An online GPCR drug discovery resource
Beyond GPCRs, the other well-established target families include enzymes, ion channels, nuclear receptors, and protein kinases. Enzymes catalyze chemical reactions in the body, and blocking specific enzymes can stop disease processes; statins, for instance, inhibit an enzyme involved in cholesterol production. Ion channels control the flow of charged particles across cell membranes and are the targets of many heart rhythm drugs, anesthetics, and anti-seizure medications. Nuclear receptors sit inside cells and regulate gene expression in response to hormones like estrogen and cortisol. One early survey catalogued 445 drugs targeting enzymes, 223 targeting GPCRs, 210 targeting ion channels, and 54 targeting nuclear receptors.4PubMed Central. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces
Protein kinases have become especially important in cancer treatment. These enzymes add chemical tags to other proteins, switching cellular pathways on or off. Many cancers are driven by kinases that are stuck in the “on” position, so drugs that block them can slow or stop tumor growth. Dozens of kinase inhibitors have been approved for cancers, though the fact that many kinases share a similar structure makes it hard to design drugs that hit only the intended one without affecting related kinases, which can cause toxicity.5PubMed Central. An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases
Where a Drug Binds on Its Target Makes a Difference
Drugs do not all grab onto the same spot on a protein. Some bind at the “active site,” the pocket where the protein does its main job. These are called orthosteric drugs. Others bind at a completely different location on the protein’s surface and change its shape so the active site works differently. These are called allosteric drugs, and the distinction has real consequences for how medicines are designed.
The central problem with orthosteric drugs is that related proteins in the body often share very similar active sites. A drug intended for one enzyme can accidentally fit into the active site of a cousin enzyme and disrupt it, leading to side effects. The solution is to make the drug bind extremely tightly to the intended target so it can be given at very low doses, reducing the chance it drifts to the wrong protein. Allosteric drugs face a different challenge: because they work by nudging the protein’s shape rather than plugging its active site, their effects can be subtler and harder to predict, but they can also achieve selectivity that is difficult for orthosteric drugs to match.6PubMed Central. The different ways through which specificity works in orthosteric and allosteric drugs
How Researchers Find and Confirm New Targets
There are two broad strategies for discovering drugs, and they relate differently to targets. In target-based discovery, scientists start by picking a protein they believe is involved in disease, then design a molecule to interact with it. In phenotypic discovery, scientists screen compounds against cells or whole organisms, looking for ones that produce a desired effect, and only afterward work out which protein the compound was hitting. A landmark analysis found that phenotypic approaches have actually been more successful at producing first-in-class medicines, partly because they do not require you to guess the right target in advance.7PubMed. Phenotypic vs. target-based drug discovery for first-in-class medicines
Target-based discovery remains the dominant approach, but it demands rigorous validation. A target looks promising in the lab; the question is whether modifying it will actually help patients. Animal studies are a standard validation step, though their results do not always translate to humans, and poor study design can muddy the picture.8PubMed. Identifying and validating novel targets with in vivo disease models: guidelines for study design For neglected tropical diseases, the challenge is even steeper: there are very few fully validated targets, and the failure rate in target-based programs for these diseases is high.9PubMed Central. Drug discovery for neglected diseases: molecular target-based and phenotypic approaches
One of the most powerful newer tools for identifying targets is CRISPR screening. By systematically turning genes on or off across an entire genome, researchers can see which genes, and therefore which proteins, are essential for a disease process or for a drug’s effectiveness. Combined CRISPR screens were used to resolve a years-long debate about the drug rigosertib, which had entered late-stage clinical trials for a blood cancer without anyone being sure how it actually worked. The screens pinpointed microtubule destabilization as the real mechanism, settling the controversy over several previously proposed targets.10PubMed Central. CRISPR approaches to small molecule target identification CRISPR-based screening has since become a go-to method for finding potential targets in cancer, cardiovascular disease, and neurodegeneration.11Experimental & Molecular Medicine. Perturbomics: CRISPR–Cas screening-based functional genomics approach for drug target discovery
Why So Many Drug Candidates Fail
Even when a target seems solid, the path from laboratory to pharmacy shelf is treacherous. Many candidates fail because the target was never truly validated in the first place, or because the animal models used to test the drug did not predict what would happen in humans, or because the drug itself had problems with absorption, toxicity, or dosing.12Journal of Integrative and Translational Biomedicine. Drug Development Failure from Preclinical, Clinical, and Industrial Perspectives Weak target validation is one of the most commonly cited reasons for clinical trial failure. A drug can work beautifully against a protein in a dish and still fail in a patient because that protein turned out not to be as central to the disease as researchers assumed.
In cancer specifically, drug resistance adds another layer. Tumors evolve. They can mutate the target protein so the drug no longer binds, ramp up alternative pathways that bypass the blocked target, pump the drug out of cells before it can act, or suppress the cell-death pathways the drug was trying to activate.13PubMed Central. The Different Mechanisms of Cancer Drug Resistance: A Brief Review This is why oncologists often combine drugs aimed at different targets: it is harder for a tumor to evolve resistance to two or three simultaneous attacks.
Off-Target Effects Are Not Always Bad
Most small-molecule drugs interact with proteins beyond their intended target.14PubMed Central. Novel Computational Approach to Predict Off-Target Interactions for Small Molecules These off-target interactions are a major source of side effects and a reason drugs get pulled from the market. But they can also be serendipitous. Some drugs that were designed for one condition turn out to have anticancer activity through off-target effects, and researchers are systematically mining these accidental interactions to find new uses for existing medicines.15PubMed Central. Turning liabilities into opportunities: Off-target based drug repurposing in cancer Drug repurposing based on off-target activity is attractive because the drug has already passed safety testing, which can dramatically shorten the timeline to patient use.
Confirming that a drug is actually engaging its intended target in living cells, rather than just producing an effect through some unknown off-target mechanism, used to be difficult. A technique called the cellular thermal shift assay, or CETSA, changed that. It exploits a simple physical principle: when a drug binds to a protein, that protein becomes slightly more heat-stable. By heating cells and measuring which proteins resist unfolding, researchers can directly observe drug-target engagement inside intact cells and tissues.16PubMed. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay This helps distinguish a drug that works by hitting its intended target from one that works by accident.
Genetic Variation Can Change How a Target Responds to a Drug
Two people can take the same drug at the same dose and have very different responses, and the drug target itself is sometimes the reason. Natural genetic variations in receptor proteins can alter how strongly a drug binds, which downstream signals it triggers, or whether an emergency reversal agent will work as expected. Research on the mu-opioid receptor illustrates this vividly. Certain naturally occurring variants of this receptor responded normally to the body’s own opioid signals but showed dramatically increased sensitivity to synthetic opioids like buprenorphine, raising the risk of accidental overdose. Other variants maintained signaling even when treated with naloxone, the standard overdose-reversal drug, which could mean naloxone would be less effective in people carrying those variants.17Cell. Pharmacogenomic Landscape of the Human G Protein-Coupled Receptor Addome
This is where the broader idea of precision medicine comes in. By sequencing a patient’s tumor or genome, doctors can identify specific mutations that make a cancer vulnerable to a targeted drug. Studies have consistently shown that patients matched to targeted therapies based on their molecular profile live longer than those given standard treatment. In one analysis of non-small-cell lung cancer, patients who received molecularly targeted therapy had a median survival of about 29 months compared to roughly 7 months for those without a targeted option.18PubMed Central. Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment Those are not small differences; they underscore why identifying the right target and confirming a patient’s tumor actually carries it can be a matter of life and death.
Reaching the “Undruggable” Proteins
For decades, a large fraction of the proteins known to drive disease were considered “undruggable” because they lacked the neat binding pockets that conventional small-molecule drugs need. Transcription factors, scaffold proteins, and many signaling regulators fall into this frustrating category. Two emerging strategies are changing the picture.
The first targets RNA instead of protein. If you cannot block a harmful protein after it has been made, you can prevent it from being made in the first place by destroying or silencing the RNA instructions that cells use to produce it. Oligonucleotide therapies, including RNA interference and antisense approaches, can reach over 10,000 proteins in the human genome that have been considered undruggable by traditional means.19PubMed Central. Targeting RNA: A Transformative Therapeutic Strategy These therapies use short, synthetic stretches of nucleic acid that match the target RNA sequence and mark it for destruction or block its translation into protein.20PubMed Central. RNA therapeutics: RNAi and antisense mechanisms and clinical applications Several RNA-targeting drugs have already been approved, and dozens more are in clinical trials for conditions ranging from cancer to neurodegeneration.
The second strategy is called targeted protein degradation. Instead of blocking a problem protein’s activity, you trick the cell’s own waste-disposal system into destroying it entirely. PROTACs (proteolysis targeting chimeras) are molecules designed with two arms: one grabs the disease-causing protein, and the other recruits the cell’s protein-recycling machinery. The result is that the target protein gets tagged for demolition and broken down. Because PROTACs work by triggering destruction rather than simply sitting in a binding pocket, they can act on proteins that lack traditional druggable sites, and they function at very low doses because each molecule can catalyze the degradation of multiple copies of the target.21PubMed Central. Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms
How AI Is Reshaping Target Discovery
Protein structure prediction has been one of the most celebrated applications of artificial intelligence in biology. Tools like AlphaFold can predict how a protein folds into its three-dimensional shape with remarkable accuracy, and that shape is exactly what researchers need to evaluate whether a protein is druggable and to design molecules that fit its binding pockets. AlphaFold has accelerated the characterization of orphan proteins, proteins whose structures were previously unknown, and helped identify targets that traditional experimental methods had overlooked.22Results in Engineering. Harnessing AlphaFold: Applications in disease understanding, drug discovery, and vaccine design
Deep-learning-based molecular docking goes a step further by predicting how tightly a drug candidate will bind to a predicted protein structure. In psychiatric drug research, for example, this combination was used to map the binding affinities of antipsychotic drugs like clozapine and olanzapine across a range of neurological, immunological, and metabolic receptors, revealing high affinity for receptors that had not been widely studied as targets for those drugs.23PubMed Central. Target Discovery Using Deep Learning-Based Molecular Docking and Predicted Protein Structures With AlphaFold for Novel Antipsychotics This kind of broad computational screening can surface unexpected connections between existing drugs and new targets, opening doors for repurposing.
The Orphan Receptor Problem
Among GPCRs alone, roughly 100 non-sensory receptors are still classified as orphans, meaning no one has identified the natural molecule that activates them.2PubMed Central. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? This matters because you cannot fully understand what a receptor does until you know what signal it normally responds to. Deorphanizing these receptors, pairing them with their natural ligands, is one of the quieter frontiers in drug-target research. Progress has been slow because many orphan GPCRs may respond to unusual stimuli, or may require complex conditions that standard laboratory screens miss.24PubMed Central. Orphan G protein-coupled receptors: the ongoing search for a home Every time an orphan receptor is successfully paired with its natural signal, it potentially opens a new avenue for drug development: a new lock for which keys can be designed.